HK185996A - Mometasone furoate monohydrate, process for making same and pharmaceutical compositions - Google Patents

Mometasone furoate monohydrate, process for making same and pharmaceutical compositions Download PDF

Info

Publication number
HK185996A
HK185996A HK185996A HK185996A HK185996A HK 185996 A HK185996 A HK 185996A HK 185996 A HK185996 A HK 185996A HK 185996 A HK185996 A HK 185996A HK 185996 A HK185996 A HK 185996A
Authority
HK
Hong Kong
Prior art keywords
monohydrate
mometasone furoate
furoate
methyl
dione
Prior art date
Application number
HK185996A
Other languages
German (de)
English (en)
French (fr)
Inventor
Yuen Pui-Ho
Eckhart Charles
Etlinger Teresa
Levine Nancy
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK185996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK185996A publication Critical patent/HK185996A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK185996A 1990-09-10 1996-10-03 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions HK185996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10

Publications (1)

Publication Number Publication Date
HK185996A true HK185996A (en) 1996-10-11

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
HK185996A HK185996A (en) 1990-09-10 1996-10-03 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Country Status (35)

Country Link
US (1) US6180781B1 (enExample)
EP (1) EP0548114B1 (enExample)
JP (1) JPH0725789B2 (enExample)
KR (1) KR960013445B1 (enExample)
CN (1) CN1030920C (enExample)
AT (1) ATE113604T1 (enExample)
AU (1) AU663471B2 (enExample)
BG (1) BG60755B2 (enExample)
CA (1) CA2091360C (enExample)
CZ (1) CZ281318B6 (enExample)
DE (2) DE19875032I2 (enExample)
DK (1) DK0548114T5 (enExample)
EE (1) EE02962B1 (enExample)
ES (1) ES2065701T3 (enExample)
FI (1) FI111078B (enExample)
HK (1) HK185996A (enExample)
HR (1) HRP920383B1 (enExample)
HU (1) HU213401B (enExample)
IE (1) IE67056B1 (enExample)
IL (1) IL99437A (enExample)
LU (1) LU90366I2 (enExample)
MX (2) MX9203396A (enExample)
MY (1) MY106644A (enExample)
NL (1) NL980012I2 (enExample)
NO (1) NO300548B1 (enExample)
NZ (1) NZ239711A (enExample)
OA (1) OA09772A (enExample)
PH (1) PH30443A (enExample)
PL (1) PL165803B1 (enExample)
PT (1) PT98905B (enExample)
SI (1) SI9111497A (enExample)
TW (2) TW229208B (enExample)
WO (1) WO1992004365A1 (enExample)
YU (1) YU48666B (enExample)
ZA (1) ZA917148B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0548114T5 (da) * 1990-09-10 1995-01-30 Schering Corp Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
PT2435025T (pt) 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) * 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
DK0548114T5 (da) * 1990-09-10 1995-01-30 Schering Corp Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette

Also Published As

Publication number Publication date
FI931031L (fi) 1993-03-09
CZ281318B6 (cs) 1996-08-14
NZ239711A (en) 1992-09-25
BG60755B2 (bg) 1996-02-29
ATE113604T1 (de) 1994-11-15
IL99437A0 (en) 1992-08-18
HU213401B (en) 1997-06-30
DE69104991D1 (de) 1994-12-08
NL980012I2 (nl) 2004-11-01
IE913155A1 (en) 1992-03-11
CN1030920C (zh) 1996-02-07
SI9111497A (sl) 1998-04-30
HUT64361A (en) 1993-12-28
FI111078B (fi) 2003-05-30
CA2091360C (en) 1997-04-08
OA09772A (en) 1993-11-30
EP0548114A1 (en) 1993-06-30
ES2065701T3 (es) 1995-02-16
FI931031A0 (fi) 1993-03-09
HRP920383B1 (en) 2000-04-30
KR960013445B1 (ko) 1996-10-05
NO300548B1 (no) 1997-06-16
MX9100990A (es) 1992-05-04
DE19875032I2 (de) 2007-04-19
ZA917148B (en) 1992-08-26
PT98905B (pt) 1998-08-31
MX9203396A (es) 1992-07-31
EP0548114B1 (en) 1994-11-02
YU48666B (sh) 1999-06-15
PH30443A (en) 1997-05-09
IL99437A (en) 1995-05-29
CA2091360A1 (en) 1992-03-11
HU9300685D0 (en) 1993-06-28
AU663471B2 (en) 1995-10-12
IE67056B1 (en) 1996-02-21
JPH05506667A (ja) 1993-09-30
CN1059911A (zh) 1992-04-01
NO930693D0 (no) 1993-02-26
PL165803B1 (pl) 1995-02-28
HRP920383A2 (en) 1998-06-30
TW272195B (enExample) 1996-03-11
YU149791A (sh) 1994-01-20
JPH0725789B2 (ja) 1995-03-22
WO1992004365A1 (en) 1992-03-19
AU8497491A (en) 1992-03-30
DE69104991T2 (de) 1995-04-20
DK0548114T5 (da) 1995-01-30
PT98905A (pt) 1992-09-30
TW229208B (enExample) 1994-09-01
US6180781B1 (en) 2001-01-30
LU90366I2 (fr) 1999-05-05
EE02962B1 (et) 1997-02-17
MY106644A (en) 1995-07-31
CZ38393A3 (en) 1994-01-19
NO930693L (no) 1993-02-26
NL980012I1 (nl) 1998-05-06

Similar Documents

Publication Publication Date Title
EP0548114B1 (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP2002531527A (ja) マクロライドの安定化
JPS62501706A (ja) エアゾル用に適するよう物理的に修正されたベクロメタソンジプロピオネ−ト
CN119019375A (zh) 一种瑞司美替罗新晶型及其制备方法
IE75695B1 (en) 3-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo [4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate
KR102210848B1 (ko) 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법
US5693814A (en) Crystals of antimicrobial compound
US20240199642A1 (en) Method for obtaining rifapentine with a new crystalline form
WO2023137966A1 (zh) 一种徳拉沙星葡甲胺盐新晶型及其制备方法
EP0101170B1 (en) Process for the manufacture of sodium cefoperazone
GB2410948A (en) Novel phosphoric acid salt of rosiglitazone
AU650572B2 (en) Crystalline etoposide 4'-phosphate diethanolate
JP2001002689A (ja) 結晶質ｌ−アスコルビン酸−２−リン酸エステルナトリウム塩およびその製造方法
WO2015180549A1 (zh) L-丙氨酸-（14-冬凌草甲素）酯三氟乙酸盐的i型结晶及制备方法
JPS6351145B2 (enExample)
US4003891A (en) Preparation of metal complexes of 6-methoxy-1-phenazinol 5,10 dioxide
GB2421240A (en) Phosphoric acid salt of rosiglitazone

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20110905